Abstract
Background
We reviewed a contemporary, single-institution experience to evaluate the natural history of stage-IV melanoma metastatic to the lung and identify factors predictive of survival.
Methods
A search of our prospective database was performed to identify patients with stage-IV melanoma and pulmonary metastases as the initial disease site; only patients seen at our institution prior to developing stage-IV disease and in whom treatment response was available were included. Patients’ demographic, clinical, and treatment variables were recorded. Cox regression was used to identify factors independently predictive of survival.
Results
The study cohort was comprised of 122 patients. Median survival was 14 months (5-year survival of 8%). Clinical factors at time of diagnosis of stage IV independently predictive of survival were a solitary pulmonary metastasis (HR 2.7, CI 1.6–4.4, P<0.0005) and absence of extra-pulmonary disease (HR 1.9, CI 1.2–3.1, P = 0.01). Among treatment factors, only metastasectomy was independently predictive of survival (HR 0.42, CI 0.21–0.87, P = 0.02). Of the patients, 26 (21%) underwent metastasectomy, with a median survival of 40 months compared with 13 months in patients not selected for surgical treatment. Of these 26, 23 (88%) experienced recurrence at a median of 5 months after the procedure. No survival difference was seen between responders and non-responders to systemic therapy (P = 0.55).
Conclusions
In stage-IV melanoma with pulmonary metastases, a solitary metastasis and absence of extra-pulmonary disease are predictive of survival. While these factors are often present in patients selected for pulmonary metastasectomy, this independently predicts survival. However, response to systemic therapy does not correlate with a survival difference.
Similar content being viewed by others
References
Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79(12):2345–2353
Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181(3):193–201
Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000; 18(22):3782–3793
Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1(2):126–134
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19(16):3622–3634
Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110(1):119–129
Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 2007; 133(1):104–110
Harpole DH Jr, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992; 103(4):743–750
Andrews S, Robinson L, Cantor A, DeConti RC. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control 2006; 13(3):218–223
Mathisen DJ, Flye MW, Peabody J. The role of thoracotomy in the management of pulmonary metastases from malignant melanoma. Ann Thorac Surg 1979; 27(4):295–299
Leo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000; 83(5):569–572
Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 1990; 107(3):256–261
Gorenstein LA, Putnam JB, Natarajan G, Balch CA, Roth JA. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg 1991; 52(2):204–210
Thayer JO Jr, Overholt RH. Metastatic melanoma to the lung: long-term results of surgical excision. Am J Surg 1985; 149(4):558–562
Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol 1998; 69(4):206–211
Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004; 139(9):961–967
Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994; 115(3):295–302
Pogrebniak HW, Stovroff M, Roth JA, Pass HI. Resection of pulmonary metastases from malignant melanoma: results of a 16-year experience. Ann Thorac Surg 1988; 46(1):20–23
Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg 1988; 123(9):1091–1095
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16):3635–3648
Sasse A, Sasse E, Clark L, Ulloa L, Clark O. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007(1):CD005413
Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002; 9(8):762–770
Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol 2006; 94(4):344–351
Acknowledgements
Heather Neuman is an Research Fellow of the Agency for Healthcare Quality and Research and this study was supported by grant number 5 T32 HS0000066.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Neuman, H.B., Patel, A., Hanlon, C. et al. Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival. Ann Surg Oncol 14, 2847–2853 (2007). https://doi.org/10.1245/s10434-007-9448-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-007-9448-y